Related by context. All words. (Click for frequent words.) 86 Granted Orphan Drug 84 Receives Orphan Drug Designation 83 Receives Fast Track 82 Completes Patient Enrollment 82 Initiates Enrollment 82 Initiates Clinical Trial 81 Files IND 81 Initiates Clinical 81 Receives Milestone Payment 81 Submits NDA 80 Presents Positive 80 Initiates Phase II 80 Receives Approvable Letter 80 Presents Preclinical Data 80 Initiates Phase III 79 Fast Track Status 79 Completes Enrollment 79 Meets Primary Endpoint 78 Therapeutic Competitors Companies 78 Phase 2b Clinical Trial 78 Drug Candidate 78 Present Preclinical Data 77 Initiates Dosing 77 Receive Milestone Payment 77 Submits Biologics License Application 77 Patient Enrollment 77 Demonstrates Significant 77 FDA Accepts 77 Investigational Compound 77 Clinical Trial Results 77 Begins Dosing 77 Demonstrates Positive 76 Novel Oral 76 Reports Preclinical Data 76 Grants Orphan Drug 76 Presents Preclinical 76 Successfully Completes Phase 76 Submits Response 76 Initiate Clinical Trial 76 Develop Novel 76 Reveals Positive 76 Phase IIb Clinical Trial 76 FDA Clears 75 Receives Positive Opinion 75 Vaccine Adjuvant 75 BioSante Pharmaceuticals Announces 75 Announces Initiation 75 Initiates Clinical Trials 75 Commences Phase 75 Submits Supplemental 75 Preclinical Data 75 R MSCRAMM 75 Announces Poster Presentations 75 Announces FDA Clearance 75 Announces Tentative Approval 75 pralatrexate injection folate analogue 75 Expanded Indication 75 Files Investigational 75 Patent Covering 75 Announce License Agreement 75 Achieves Primary Endpoint 75 Submits IND 75 First Patient Enrolled 75 Milestone Payment 75 Antibody Drug Conjugate 74 Taro Receives 74 Gets FDA Clearance 74 Licenses Novel 74 Personalized Immunotherapy 74 Combination REOLYSIN R 74 Systemic Delivery 74 Receives CE Marking 74 Submits Application 74 Oral Calcitonin 74 Initiates Phase 74 Completes Dosing 74 FDA Approvals 74 Psoriasis Drug 74 Presents Positive Preclinical 74 Phase 2b Trial 74 Pivotal Phase III 74 Earns Milestone Payment 74 JAK2 Inhibitor 74 Phase III Clinical Trial 74 FDA Orphan Drug 74 Collaborators Present 74 Crofelemer budesonide foam 74 Initiate Phase III 74 Lupus Drug 74 Orphan Drug designations 74 Pivotal Study 74 Investigational Treatment 74 RNAi Therapeutic 74 Enrolls First 74 Demonstrates Potential 73 NDA Submission 73 Immunomedics Announces 73 IND Filing 73 Xcytrin R 73 RNAi Therapeutics 73 Lung Cancer Drug 73 PRN FDA Approves 73 Regains NASDAQ 73 Launches Generic Version 73 FOLOTYN ® 73 vapreotide acetate 73 FDA Okays 73 Teva Provides Update 73 Flamel Technologies Announces 73 Receives Complete Response 73 Prolongs Survival 73 Phase 2a Trial 73 Migraine Drug 73 Milestone Payments 73 Anti Tumor 73 Pafuramidine 73 Small Molecule 73 Phase IIb Trial 73 Drug Fails 73 Awarded Qualifying Therapeutic 73 visit www.genenews.com 73 Mylan Receives Approval 72 Receives FDA Clearance 72 First Patient Treated 72 Initiate Phase 72 Inc Therapeutic Competitors 72 lead molecular radiotherapeutic 72 Collaborators Publish 72 Advanced Melanoma 72 FDA APPROVES 72 Adjuvant Treatment 72 Hsp# Inhibitor 72 Therapeutic Competitors companiesandmarkets.com adEgemonye 72 Positive Opinion 72 Epilepsy Drug 72 Study Evaluating 72 Shows Promising 72 Receives Patent 72 Improves Survival 72 Antitumor Activity 72 Pegloticase 72 Novel Antibiotic 72 Announce Licensing Agreement 72 markets COLAZAL 72 Demonstrates Sustained 72 Prostate Cancer Vaccine 72 DOR BioPharma Announces 72 Shows Efficacy 72 Gout Drug 72 Receives NASDAQ 72 R lenalidomide 72 Trial Evaluating 72 Tezampanel 72 candidates Azedra 72 Vitrasert R 72 Rheumatoid Arthritis Drug 72 Investigational Drug 72 Receives Tentative Approval 72 Phase III Trial 72 SABER ™ 72 Telik logo TELINTRA 72 Pivotal Trial 72 VIVUS Announces 72 GATTEX TM 72 PDUFA Date 72 VIVITROL ® 72 Announce Initiation 72 JAK Inhibitor 72 Demonstrates Efficacy 72 Phase 1b Clinical Trial 72 Patients Treated With 72 Drug Shows Promise 71 Orphan Status 71 candidates Azedra TM 71 HCV Protease Inhibitor 71 Initiates Phase 2b 71 Jumps Higher 71 Generic Version 71 Reports Positive 71 methylnaltrexone bromide 71 Phase IIa Clinical Trial 71 Oral Mucositis 71 Announces License Agreement 71 Transdermal Patch 71 molecular imaging radiopharmaceutical 71 Immunotherapeutic 71 Study Demonstrates 71 Announce Merger Agreement 71 Issued Patent 71 Improves Outcomes 71 Receives Positive 71 Osteoporosis Drug 71 Announce Collaboration Agreement 71 TRANSDUR ® 71 Arthritis Drug 71 Alvine Pharmaceuticals 71 MOVIPREP R 71 platform HDL Mimetic 71 Hematological Malignancies 71 Begins Shipment 71 First Patient Dosed 71 subsidiaries visit http:/www.apricusbio.com 71 Completes Patient Enrolment 71 Significantly Improves 71 Oral Fingolimod 71 Sign Licensing Agreement 71 Shows Promise Against 71 Key Milestones 71 Announces Publication 71 Veronate R 71 Submits Investigational 71 highly purified pasteurized 71 Nuvelo Announces 71 CysDisplay R 71 Shows Statistically Significant 71 Preclinical Models 71 Pivotal Phase 71 Kinase Inhibitor 71 Preclinical Study 71 Nasdaq VNDA 71 Begin Clinical Trials 71 Single Dose 71 Introduces Novel 71 COLAZAL R 71 Receives Favorable 71 Announces Licensing Agreement 71 non nucleoside inhibitor 71 Inc. www.micromet inc.com 70 Protease Inhibitor 70 Therapeutic Antibody 70 Enters Into Collaboration 70 Investigational Oral 70 TRANSDUR ™ 70 Licenses Patents 70 Million Milestone Payment 70 Sangamo BioSciences Announces 70 Panzem R 70 Announces Presentation 70 Cholesterol Lowering Drug 70 GRAS Status 70 XL# anticancer compounds 70 TM Aganocide 70 By JAMAAL ABDUL 70 Phase 2a Clinical Trial 70 DARA logo 70 Commence Phase 70 Shows Promise 70 Pooled Analysis 70 BioDelivery Sciences Announces 70 Abstract Accepted 70 Recombinant Human 70 Pharma Merck Serono 70 R bendamustine hydrochloride 70 Adjunctive Therapy 70 Alnylam Nasdaq ALNY 70 AVI BioPharma Announces 70 Survival Benefit 70 Achieves Milestone 70 Clinical Trial Evaluating 70 Aztreonam Lysine 70 Kuvan R 70 developing Zerenex ferric 70 sapropterin dihydrochloride 70 Receives Marketing Authorization 70 Evoltra ® 70 Complicated Skin 70 Orphan Designation 70 Ecallantide 70 Supplemental Biologics License Application 70 Peginterferon alfa 2b 70 Orally Active 70 oncolytic virus therapies 70 Therapeutic Competitors Report 70 please visit http:/www.vandapharma.com 70 Announces Positive 70 Topline Results 70 Spectrum Pharmaceuticals Announces 70 Antitumor 70 BiovaxID TM 70 Investigational Agent 70 ALTROPANE R 70 markets HP Acthar 70 Previously Treated 70 Chronic Hepatitis C 70 GTC recombinant form 70 Data Suggest 70 Inc. Nasdaq OXGN 70 Alfacell proprietary ribonuclease 70 Regeneron Pharma 70 Generic Versions 70 TRACON Pharmaceuticals 70 MKC# MKC# PP 70 Employment Inducement Awards 70 Reacquires 70 Onyx Pharmaceuticals Announces 70 RANK Ligand inhibitor 70 ® decitabine 70 Aloxi ® 70 Molecular Diagnostic Test 70 Severe Sepsis 70 Lupus Nephritis 70 FUSILEV ® 70 Announce Licensing 70 Anticancer Drug 70 Provides Update Regarding 69 targeted radiotherapeutic 69 Patient Enrolment 69 Zorbtive TM 69 novel emulsion formulation 69 Monoclonal Antibody 69 Bafetinib 69 Dyax logo 69 Oral Laquinimod 69 ELADUR TM 69 Recommends Approval 69 Anti CD# Antibody 69 AAG geldanamycin analog 69 HuMax TAC 69 toenail onychomycosis 69 Disease Modifying 69 Obtains Exclusive License 69 Significantly Reduces 69 novel proprietary KL4 69 Identifies Potential 69 developing Bicifadine serotonin 69 GVAX ® 69 FDA Clearance 69 Sign License Agreement 69 Aeolus Pharmaceuticals Announces 69 novel synthetic PEGylated 69 Files Shelf Registration Statement 69 Receives Clearance 69 Novel Therapeutic 69 Pharmacyclics Announces 69 KRYSTEXXA TM pegloticase 69 VentiRx Pharmaceuticals 69 Obtains License 69 Regenerative Cells 69 Amigal TM 69 product platforms AZX# 69 please visit www.dyax.com 69 Files Patent Application 69 Sagent Pharmaceuticals Announces 69 Poniard Pharmaceuticals Announces 69 PDL BioPharma Announces 69 Orphan Drug status 69 Paris IPN Euronext 69 Proven Effective 69 delivers fluocinolone acetonide FA 69 please visit http:/www.atherogenics.com 69 Novel Antibody 69 Transcept Pharmaceuticals 69 SPRYCEL ® 69 IMiDs ® 69 Novel Mechanism 69 TO AVOID PREGNANCY WHILE 69 Dose Escalation 69 PPD Declares 69 please visit www.abraxane.com 69 Nanophase Announces 69 Therapeutic Competitors 69 MBRX 69 Confirmatory Phase 69 Voluntarily Withdraw 69 IND Application 69 Iluvien ® 69 Nasdaq XTLB 69 Nicotine Vaccine 69 palonosetron hydrochloride Injection Dacogen 69 Schizophrenia Drug 69 peptidic compound 69 COLLABORATION WITH 69 Therapeutic Vaccine 69 Novel Treatments 69 XIAFLEX ® 69 VYVANSE TM lisdexamfetamine 69 FDA Approves 69 Clinical Trial Data 69 Receives SFDA Approval 69 ORADUR ® 69 R Saizen R 69 R bortezomib 69 Clinical Outcome 69 Aurora Kinase 69 Boehringer Ingelheim MedImmune 69 Tumor Targeting 69 Oracea TM 69 markets XIFAXAN ® 69 Namenda Memantine HCl 69 Mouse Model 69 Receives Notification 69 substantially excreted 69 Phase III Trials 69 Unanimously Recommends Approval 69 Flagship Product 69 IMiDs ® compound 69 Awarded Patents 69 Anticancer Agent 69 Broadens Its 69 Idenix Novartis 69 refractory chronic lymphocytic 69 novel orally inhaled 69 Sinks Lower 69 Antisense Drug 69 Demonstrates Potent 69 DNA methyltransferase inhibitors 69 STERIS Corporation Announces 69 balsalazide disodium Capsules 69 IN PATIENTS WITH 68 Cardium Therapeutics TM 68 Febuxostat 68 novel MetAP 2 68 Extends Collaboration 68 Nasdaq PARD 68 Aflibercept 68 Milestone Payment From 68 Long Term Efficacy 68 Phase 2b Study 68 Settle Patent Litigation 68 sitaxsentan sodium 68 Solazed ™ 68 TELINTRA R 68 Tyrosine Kinase Inhibitor 68 Anticancer Compound 68 acetonide FA 68 small molecule Hedgehog 68 Kuvan TM sapropterin 68 BioElectronics Announces 68 Effectively Treats 68 Combination Treatment 68 Novel Inhibitor 68 Somatuline Depot 68 Nasdaq CTIC 68 Ridaforolimus 68 AUDIO PROVIDED BY 68 HuCAL PLATINUM R 68 Resubmission 68 Xeloda ® 68 www.palatin.com 68 Maven Semantic 68 ODT metoclopramide HCl PEPCID 68 Inhaled Insulin 68 orally administered inhibitor 68 NeutroPhase TM 68 Vaccine Protects Against 68 Salix Pharmaceuticals Announces 68 selective estrogen receptor modulator 68 Trastuzumab DM1 68 IG HCR ;) CO 68 IMiDs R 68 Romiplostim 68 Amends Agreement 68 ANDA Filing 68 Entereg R 68 ARCALYST R 68 visit www.sciclone.com 68 MEK Inhibitor 68 Generic Version Of 68 Biomarker Study 68 ALN HPN 68 Intravenous Formulation 68 oral prodrug 68 Commercialize Novel 68 PROVENGE ® 68 mGluR2 positive 68 ALN PCS 68 R sorafenib tablets 68 ABLYNX 68 developing ostarine selective 68 Treatment Naïve 68 Confirms Efficacy 68 Maribavir 68 Roche OTC RHHBY 68 Cypher Sirolimus 68 hyaluronidase enzyme 68 Romidepsin 68 HuCAL PLATINUM ® CysDisplay 68 Receives Conditional 68 Strengthens Balance Sheet 68 NUEDEXTA ™ 68 Bazedoxifene 68 CYT# potent vascular disrupting 68 Patent Issued 68 pentadentate logo R 68 Kosan dependence 68 Demonstrates Statistically Significant 68 Expands Scientific Advisory 68 BIOTECHNOLOGY SOURCE 68 FDA Approvable Letter 68 Phase III Pivotal 68 PEGylated Fab fragment 68 Anti Tumor Activity 68 Potassium Chloride Sodium Ascorbate 68 Taglich Brothers Initiates Coverage 68 Rotavirus Vaccine 68 Glufosfamide 68 Nasdaq Deficiency Notice 68 Valortim TM 68 Renal Cancer 68 Prodarsan R 68 CAMPATH R 68 Inc. Nasdaq IMGN 68 Phase 2a Study 68 Multiple Ascending Dose 68 lexidronam injection 68 compound ISA# 68 Sunesis Pharma 68 PNP inhibitor 68 Metabolic Disorder 68 Projected Release Date 68 Oral Formulation 68 product candidate Lpathomab 68 Double Blind Placebo 68 visit http:/www.mannkindcorp.com 68 HDAC Inhibitor 68 Provectus Pharmaceuticals specializes 68 Regains Compliance With 68 Levoleucovorin 68 Methylnaltrexone 68 OMAPRO ™ 68 Patients Suffering 68 markets Testim ® 68 Exherin 68 Aganocide 68 Potelligent Technology 68 INSPIRE Trial Phase III 68 Subsidiary Enters 68 Sapacitabine 68 initiated Phase Ib 68 includes TOLAMBA TM 68 rusalatide acetate 68 Acute Attacks 68 Telik Announces 68 Pivotal Clinical Trial 68 Oral Solution OSMOPREP 68 ® adefovir dipivoxil 68 BioElectronics Corporation Announces 68 REG1 Anticoagulation System 68 Archexin 68 Polymerase Inhibitor 68 Disease IBD 68 Significantly Improved 68 R famotidine 68 ® bortezomib 68 Hormone Refractory Prostate Cancer 68 investigational pharmacologically unique 68 Epratuzumab 68 OTCBB IMUC 68 Inovio Pharmaceuticals 68 Achieves Significant 68 Announcement acc 68 Successfully Treated 68 Attains Gold Certified Partner 68 MKC# MT 68 Agonist MABA program 68 BCG refractory carcinoma 68 Elagolix 68 BiTE Antibody 68 Well Tolerated 68 5q MDS 68 Regains Full 68 Efficacy Results 68 Soft Tissue Sarcoma 68 Humanized Anti 68 GTC NASDAQ GTCB 68 ZEVALIN ® 68 Pathway Inhibitor 68 Provides Shareholder 68 topically applied SEPA 68 Sodium Sulfate Sodium Chloride 68 Renal Cell Carcinoma 68 Kinase Inhibitors 68 http:/www.unigene.com 68 Liprotamase 68 Acute Heart Failure 68 Novel Compound 68 granted orphan medicinal 68 submitted Biologics License 68 dihydrochloride Tablets 68 Vascular Disrupting Agent 68 PRAECIS PHARMACEUTICALS INCORPORATED 68 Receives ISO #:# [002] 68 Secondary Hyperparathyroidism 68 Low Dose 67 Secures Additional 67 therefore therapeutically equivalent 67 Visit www.BASInc.com 67 essential thrombocythemia ET 67 Awarded Patent 67 candidate REP# 67 Reduces Risk 67 molecular therapeutics immunotherapies 67 Pulmonary Arterial Hypertension 67 Showed Significant 67 proprietary intravenous formulation 67 DIFICID ™ 67 Blood Pressure Drug 67 Prochymal TM 67 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 67 Regains Compliance 67 Receives Unsolicited 67 Intravenous Human 67 Announces Issuance 67 LibiGel ® 67 Q3 Loss Narrows 67 VISICOL R 67 Announces Favorable 67 please visit http:/www.supergen.com 67 Accelerate Commercialization 67 Announces Dosing 67 www.ucb group.com 67 Q2 Loss Narrows 67 Therapeutic Vaccines 67 candidate deforolimus 67 OTCBB GNTA 67 Bucindolol 67 Diabetic Neuropathy 67 SPL# Gel vaginal microbicide 67 please visit http:/www.sunesis.com 67 Demonstrated Significant 67 Preclinical Efficacy 67 UGNE 67 IL# PE#QQR 67 Reconfirms 67 Q3 Loss Widens 67 OTC BB PVCT 67 Improved Survival 67 FOR FURTHER INFORMATION ABOUT 67 Albuferon TM 67 Bradmer Pharmaceuticals 67 Secures Financing 67 Vicriviroc 67 Terminate Merger Agreement 67 interferon beta 1a infertility 67 Nasdaq EPCT 67 website www.celsion.com 67 OTCBB PYTO 67 neuropathic pain spasticity 67 Miraculins Announces 67 motexafin gadolinium Injection 67 Merck OSI Pharmaceuticals 67 Nasdaq HALO 67 Anti Inflammatory 67 Ovitrelle R Serostim 67 HuCAL GOLD R 67 PROSTASCINT R 67 Biogen Genentech 67 Anticancer Activity 67 Antigen Specific 67 Seasonal Influenza Vaccine 67 AVANIR Pharmaceuticals Announces 67 affiliate Evogene Ltd. TASE 67 ATRA IV 67 Tibotec BVBA 67 label Lipofen R 67 novel VDA molecule 67 Diamyd Medical Diamyd 67 ARRY # 67 topical antifungal product 67 Unsolicited Proposal From 67 Plaque Psoriasis 67 liver resection surgeries 67 Pruvel TM 67 ELADUR ™ 67 Obtains FDA 67 Isavuconazole 67 DOXIL R 67 Luveris R Ovidrel R 67 Palifosfamide 67 Solazed TM 67 Vertex Pharmaceuticals Announces 67 NexMed Receives 67 Multiple Myeloma Patients 67 Release Capsules 67 4SC AG ISIN DE# 67 Nasdaq IDIX 67 Serostim ® 67 Bosutinib 67 Nexavar prescribing 67 Develops Novel 67 Expand Collaboration 67 Vaccine Candidate 67 Cancer Vaccines 67 Patients Enrolled 67 Companion Diagnostic 67 Exploit collaboration 67 Idera Pharmaceuticals 67 Safinamide 67 Files Provisional 67 Wafer polifeprosan 67 CONBRIZA 67 DRRX 67 visit http:/www.PAREXEL.com 67 Announces Additions 67 Plicera TM 67 Signs License Agreement 67 Univest Corporation Declares 67 Desvenlafaxine Succinate 67 OTCBB FCSC 67 Oral Suspension USP 67 Ostarine ™ 67 Zemiva TM 67 Inhalation Solution 67 Successfully Treats 67 Metastatic Melanoma 67 Neulasta R 67 Prospective Randomized 67 Aradigm Logo 67 PDX pralatrexate 67 erlotinib Tarceva R 67 Sciences ABthrax Albuferon 67 Receives Tentative FDA 67 mertansine 67 include Phenoptin TM 67 Chronic Hepatitis B 67 investigational humanized monoclonal antibody 67 See CLINICAL PHARMACOLOGY 67 Corp. AMEX CVM 67 PHRM 67 TKB# 67 lintuzumab SGN 67 Frankfurt XMP 67 selective A2A adenosine receptor 67 Nasdaq Delisting Notice 67 Relapsing Multiple Sclerosis 67 Atypical Antipsychotic 67 Mg Usa 67 granted Orphan Drug 67 Nasdaq Notice Regarding 67 receptor tyrosine kinase inhibitor 67 k Clearance 67 MAGE A3 ASCI 67 please visit www.sucampo.com 67 TNF Tumor Necrosis Factor 67 successfully commercialize Iluvien 67 Prophylactic Treatment 67 rxRNA 67 Board Authorizes 67 Restructures Operations 67 COLAZAL ® 67 Receptor Agonist 67 Treated Patients 67 pharmacogenomic translational research 67 PATHFINDER R 67 REPRONEX R menotropins 67 Cutaneous T 67 Begins Clinical Trial 67 cMET 67 Ambrisentan 67 Diabetic Nephropathy 67 EntreMed Presents 67 Atopic Dermatitis 67 Lorus Therapeutics Announces 67 CYP#A# CYP#D# 67 novel therapeutic antibodies 67 Doripenem 67 Acquires Exclusive 67 Hematological Cancers 67 Lowers Risk 67 investigational oral inhibitor 67 IgG1 monoclonal antibody 67 ACAPODENE R 67 Raptiva R 67 UPLYSO 67 Invites Investors 67 ALN TTR 67 Prostate Cancer Patients 67 Syncria R 67 Fludara ® 67 Marketing Authorisation Application 67 adenosine injection 67 GTC recombinant human 67 Exelixis logo 67 anti botulism antibody 67 OMNARIS HFA 67 Randomized Phase 67 OMNARIS Nasal Spray 67 Commences Phase III 67 Updates Guidance 67 TriCo Bancshares Announces 67 Nasdaq OSIP 67 Glatiramer Acetate 67 METOZOLV TM ODT metoclopramide 67 NASH Huntington 67 Clinical Efficacy 67 THERAPEUTICS 67 Granulocyte Colony Stimulating Factor 67 CE marked PROGENSA 67 Pirfenidone 67 II Clinical Trial 67 Diabetic Foot Ulcer 67 Expands Portfolio 67 Derma Sciences Announces 67 Trobalt 67 BUPHENYL R 67 Confirms Validity 67 Japanese Encephalitis Vaccine 67 humanized therapeutic 67 CHEAP ONLINE PHARMACY LOW 66 Lymphoid 66 Completes Financing 66 Interferon Beta 66 R Bortezomib 66 Treatment Reduces 66 RECOTHROM R 66 Tigecycline 66 ASE SVA 66 SinuNase ™ 66 Patents Covering 66 Amend Merger Agreement 66 Orphan Drug designation 66 Application MAA 66 XYOTAX TM 66 Updates Shareholders 66 Augment TM 66 Antifungal 66 Commercialize 66 STELARA TM 66 SUPPRELIN R LA 66 Potent Antiviral Activity 66 IMPACS R 66 Regulatory Clearance 66 Patients Receiving 66 Bristol Myers Squibb sanofi 66 Adjuvant Chemotherapy 66 Treatment Experienced 66 Patient Treated 66 Recombinant Protein 66 Announces Successful Completion 66 Preotact R 66 cause cardiac channelopathies 66 Phase III Clinical Trials 66 NASDAQ Listing Requirements 66 Provides Guidance 66 NOTE POSIDUR ™ 66 Medisorb ® 66 Boxed Warnings 66 Budesonide foam crofelemer 66 telomerase therapeutic 66 Bone Augmentation Material 66 Auxilium Pharma 66 Inc. OTCBB ECTE 66 treat chronic sinusitis 66 Webcast Presentations 66 Patent Broadly Covering 66 Merck Serono Nycomed 66 Inc SPPI 66 using VIAdel TM 66 Nasdaq IMGN 66 Oral Spray 66 Civacir 66 Announces Adjournment 66 Heska Announces 66 Erica Elchin #-#-# 66 Synthetic Peptide 66 NASDAQ XTLB 66 Inflammatory Arthritis 66 Generx ® 66 Synta Announces 66 Receives Anticipated 66 JOULFERON 66 Epidermal Growth Factor Receptor 66 Perflubutane Polymer Microspheres 66 Parathyroid Hormone 66 Receives Regulatory 66 Testosterone Gel 66 Telaprevir VX 66 Tech DVAX 66 Myeloma Patients 66 Slows Progression 66 please visit www.middlebrookpharma.com 66 Vicor Technologies Announces 66 oral nucleoside analogue 66 targeting Inflammatory Bowel 66 agonistic human 66 Patients Treated 66 Orphan Drug Status 66 SIX RO ROG 66 website http:/www.celsion.com 66 proprietary intranasal insulin 66 topical gel formulation 66 Albugon 66 RECOTHROM ® 66 rasagiline tablets 66 visit www.targanta.com 66 BYETTA ® 66 Q1 Loss Narrows 66 Unigene nasal calcitonin 66 Lanthanum Carbonate 66 initiated Phase 1b 66 fibrosis IPF 66 derivatives Radilex TM 66 visit www.stemcellthera.com 66 M# rationally 66 Opterone R 66 Soliris eculizumab 66 Pivotal Phase II 66 SYCREST 66 Alnylam Pharma 66 Brentuximab Vedotin SGN 66 Exclusive License 66 transthyretin mediated amyloidosis ATTR 66 Inhibits 66 Inflammatory Disease 66 Restructures Debt 66 Receives CE 66 CYCLOSET ® 66 Breast Cancer Recurrence 66 Vascular Grafts 66 Onalta TM 66 myelodysplastic myeloproliferative diseases 66 Demonstrates Ability 66 small molecule thrombopoietin 66 Medicure Announces 66 Homspera TM 66 Generic Protonix 66 Announces Effective Date 66 corticotropin injection 66 monoclonal antibody IgG1 Mab 66 programs visit http:/www.bionovo.com 66 Treat Anemia 66 monoclonal antibody conjugated 66 Lifts FY# Outlook 66 Novel Anti Inflammatory 66 Mutually Agree 66 Partnering Agreements 66 LymphoStat B belimumab 66 MSCRAMM ® 66 mGluR5 negative 66 Drug Resistant 66 Hydrochlorothiazide Tablets 66 Phase Ib Clinical Trial 66 Ceflatonin R 66 PharmaVitae Profile 66 Pharmacokinetic Study 66 Isis Pharma 66 NS5b 66 Verisyse TM intraocular lenses 66 kidney urologic 66 Jointly Announce 66 TSRX 66 Successfully Concludes 66 Multicenter Phase 66 ANIK 66 Capsules CII 66 BIOLASE Announces 66 Fast Track designations 66 Synvisc ONE 66 Fibrocell Science Inc. 66 Announce Collaboration 66 Paliperidone Palmitate 66 INTEGRILIN R eptifibatide Injection 66 siRNA Delivery 66 BRILINTA 66 ADP receptor antagonist 66 Friedreich Ataxia FRDA 66 Myelodysplastic Syndromes 66 NRGN 66 nasal calcitonin product 66 Drug Prevents 66 induced macular edema 66 Adjuvanted 66 Non Invasive Treatment 66 Chronic Lymphocytic Leukemia CLL 66 MAb therapy 66 Therapeutic Potential 66 ThermoDox ® clinical 66 novel histone deacetylase 66 pan histone deacetylase 66 Therapy Improves 66 2 methoxyestradiol 66 Oral Insulin 66 Metabolic Disease 66 Refractory Hodgkin Lymphoma 66 TRIOLEX HE# APOPTONE HE# 66 researches develops licenses 66 OTCQX QRXPY 66 Genotyping Test 66 Ltd Therapeutic Competitors 66 Benign Prostatic Hyperplasia 66 Taiho Pharmaceutical 66 Strengthens Leadership 66 OvaRex R 66 HER2 Positive Breast Cancer 66 Overactive Bladder 66 Staphylococcus aureus Immune Globulin 66 Marketing Authorisation 66 Fungal Infections 66 Nasdaq ONXX 66 beta 1a 66 Explore Strategic Alternatives 66 Controlled Study 66 Strengthens Position 66 Gamunex C 66 Methylphenidate Transdermal System 66 markets Gelclair R 66 Misonix Announces 66 Darinaparsin 66 MONSTERSTOX.COM Monsterstox.com